Design Therapeutics, Inc. DSGN
We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Certain diseases caused by inherited nucleotide repeat expansion, such as Friedreich ataxia (FA) and fragile X syndrome, can result in reduced gene expression and deficiency of vital proteins; in other diseases, such as myotonic dystrophy type-1 (DM1), Fuchs endothelial corneal dystrophy (FECD), and Huntington's disease (HD), the nucleotide repeat expansions result in the generation of toxic gene products, often associated with pathological nuclear foci and broad splicing disruptions or the expression of mutant proteins that form toxic aggregates. Our GeneTAC® small molecules are designed to selectively target expanded genetic repeat sequences, modulate gene expression either by dialing up or down mRNA transcription, depending on the cause of the disease, and restore cellular health. As a platform, we believe that GeneTAC® molecules have broad potential applicability across currently unaddressed degenerative, monogenic nucleotide repeat expansion diseases affecting millions of individuals worldwide.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | $226.0K | — |
| R&D | $59.1M | $44.4M | $57.1M | $48.6M | $24.8M | $6.1M | — |
| SG&A | $20.3M | $18.0M | $21.1M | $19.0M | $11.1M | $2.5M | — |
| Total operating expenses | $79.5M | $62.4M | $78.2M | $67.6M | $35.8M | $8.6M | — |
| Operating income | -$79.5M | -$62.4M | -$78.2M | -$67.6M | -$35.8M | -$8.3M | — |
| Pre-tax income | -$69.8M | -$49.6M | — | — | — | — | — |
| Income tax | $0 | $0 | — | — | — | — | — |
| Net income | -$69.8M | -$49.6M | -$66.9M | -$63.3M | -$35.5M | -$8.3M | — |
| EPS, basic | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | — | — |
| EPS, diluted | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | -0.52 | — |
| Shares, diluted (wtd. avg.) | 57.3M | 56.6M | 56.0M | 55.7M | 45.9M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $16.9M | $22.6M | $21.2M | $26.5M | $298.6M | $2.4M | $77.0K |
| Short-term investments | $203.0M | $222.9M | $260.6M | $303.9M | $85.5M | $33.7M | — |
| Total current assets | $223.8M | $248.0M | $284.6M | $335.1M | $385.4M | $36.2M | — |
| Property, plant and equipment | $981.0K | $1.4M | $1.7M | $1.9M | $1.5M | $71.0K | — |
| Total assets | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M | $36.5M | — |
| Accounts payable | $2.3M | $2.2M | $1.9M | $3.0M | $1.6M | $1.4M | — |
| Total current liabilities | $13.1M | $8.5M | $9.6M | $10.8M | $5.3M | $2.3M | — |
| Total liabilities | $13.7M | $10.0M | $12.0M | $13.8M | $8.4M | $2.5M | — |
| Retained earnings | -$297.0M | -$227.2M | -$177.6M | -$110.8M | -$47.5M | -$11.9M | — |
| Total equity | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M | -$11.3M | -$3.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$54.4M | -$43.1M | -$58.6M | -$51.3M | -$29.4M | -$8.7M | — |
| Depreciation and amortisation | $622.0K | $596.0K | $537.0K | $406.0K | $129.0K | $5.0K | — |
| Stock-based compensation | $14.5M | $13.1M | $13.1M | $10.9M | $4.7M | $450.0K | — |
| Capital expenditure | $193.0K | $340.0K | $256.0K | $918.0K | $1.5M | $76.0K | — |
| Investing cash flow | $22.9M | $44.0M | $52.5M | -$221.0M | -$53.6M | -$33.6M | — |
| Financing cash flow | $25.7M | $513.0K | $724.0K | $235.0K | $379.2M | $44.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-098491.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $226.0K | — | — | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$8.3M | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |